Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Significant Drop in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 23,029 shares, a decline of 37.5% from the May 31st total of 36,835 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily trading volume, of 76,196 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

NEUP has been the subject of several research analyst reports. HC Wainwright lowered shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Monday, June 1st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Trading Down 3.6%

Neuphoria Therapeutics stock traded down $0.13 during midday trading on Thursday, reaching $3.42. 97,557 shares of the stock traded hands, compared to its average volume of 57,270. The firm has a market cap of $18.47 million, a PE ratio of -0.31 and a beta of 0.74. The company has a 50-day simple moving average of $4.84 and a two-hundred day simple moving average of $4.44. Neuphoria Therapeutics has a 12-month low of $3.19 and a 12-month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47. Equities research analysts anticipate that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

Institutional Investors Weigh In On Neuphoria Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC purchased a new stake in Neuphoria Therapeutics during the 4th quarter worth approximately $43,000. XTX Topco Ltd purchased a new position in Neuphoria Therapeutics in the 4th quarter valued at approximately $47,000. Persistent Asset Partners Ltd boosted its position in Neuphoria Therapeutics by 173.1% in the 4th quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after buying an additional 8,495 shares during the period. Boothbay Fund Management LLC acquired a new position in shares of Neuphoria Therapeutics in the fourth quarter worth $54,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Neuphoria Therapeutics in the fourth quarter worth $57,000. 15.90% of the stock is owned by hedge funds and other institutional investors.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.